|Bid||52.68 x 1200|
|Ask||63.50 x 800|
|Day's Range||52.60 - 53.96|
|52 Week Range||41.51 - 64.94|
|Beta (5Y Monthly)||1.10|
|PE Ratio (TTM)||29.07|
|Earnings Date||Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||57.00|
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that it has received final approval from the U.S. Food and Drug Administration ("FDA") for its novel product, PEMFEXY™ (pemetrexed for injection), a branded alternative to ALIMTA®.
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle") today announced that Eagle and the University of Pennsylvania ("Penn") have agreed on terms of a new exclusive worldwide license agreement for the development of dantrolene sodium for the potential treatment of people living with Alzheimer’s disease, including an agreement to fund additional research and provisions regarding commercialization of products developed under the license.
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle") today announced that the Company has resubmitted its New Drug Application ("NDA") for RYANODEX® (dantrolene sodium for injectable suspension) for the treatment of exertional heat stroke ("EHS"), in addition to body cooling, to the U.S. Food and Drug Administration ("FDA"). Eagle believes that this submission addresses the Complete Response Letter received in July 2017. A Prescription Drug User Fee Act ("PDUFA") date of six months is anticipated for this class of resubmissions.
Tyme's (TYME) shares rise as the company inks deal with Eagle Pharmaceuticals to co-promote its investigational cancer metabolism-based therapy, oral SM-88, in the United States.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
Shares of Tyme Technologies were up 23% in premarket trading on Tuesday after the biotechnology company said it had formed a collaboration with Eagle Pharmaceuticals Inc. to co-promote Tyme's investigational cancer treatment. Eagle's stock gained 3% before the market opened. Per the terms of the agreement, Tyme will receive $20 million upfront and an additional $20 million in milestone payments if certain endpoints are met. If the therapy, oral SM-88, is approved, Eagle is responsible for one-fourth of sales efforts and is expected to receive 15% of net revenue. The treatment has completed mid-stage trials. Tyme's stock has fallen 54% over the last year; Eagle's stock is up 40%. The S&P 500 has gained about 28% over the last 52 weeks.
Tyme Technologies, Inc. (Nasdaq: TYME) ("TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), and Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle"), today announced the formation of a U.S. strategic collaboration focused on the co-promotion of TYME’s lead CMBT candidate oral SM-88 in advanced cancers. CMBTs are proprietary investigational compounds that are believed to disrupt cancer cells’ protein synthesis, leading to a breakdown of the cancer’s key defenses and cell death. In clinical trials, oral SM-88 has demonstrated complete or partial responses across 15 different cancers, including pancreatic, prostate, sarcoma, breast, lung, and blood cancers with minimal serious grade 3 or higher adverse events.
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle") announced today a new research agreement with NorthShore University HealthSystem in Evanston, IL, focused on studying Eagle’s RYANODEX® (dantrolene sodium) for traumatic brain injury (TBI) in animal models.
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) shareholders might be concerned after seeing the share price drop 12% in the...
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -16.13% and -5.06%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted returns. […]
Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.